Tagged as: Admelog

British Columbia Expands Biosimilar Initiative to Rapid-Acting Insulins

On December 1, 2021 the government of British Columbia announced that it is further expanding its biosimilar initiative.  The statement reported that as of November 30, 2021 an estimated 30,000 patients on the rapid-acting insulin lispro (Humalog) and insulin aspart (NovoRapid) would have six months to transition to the respective…

Read More